NCT06383312

Brief Summary

In the study, easy-to-access and easy-to-use reflexologic magnetic insoles were used in women with primary dysmenorrhea who did not want to receive medical treatment; In addition to reducing symptoms such as pain, nausea, dizziness, fainting, vomiting, weakness, constipation/acute gastroenteritis, it is aimed to increase individuals' participation in daily life activities and increase their quality of life by increasing their emotional state.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started May 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 6, 2024

Completed
19 days until next milestone

First Posted

Study publicly available on registry

April 25, 2024

Completed
6 days until next milestone

Study Start

First participant enrolled

May 1, 2024

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2024

Completed
Last Updated

April 25, 2024

Status Verified

April 1, 2024

Enrollment Period

3 months

First QC Date

April 6, 2024

Last Update Submit

April 20, 2024

Conditions

Keywords

DysmenorrheaReflexologyPainFoot Orthoses

Outcome Measures

Primary Outcomes (4)

  • McGill Pain Questionnaire-Short Form:

    It evaluates the sensory dimension of pain and the affective dimension of pain. Affective and sensory dimension scores of pain are measured with a Likert-type scale (0-No pain, 3-Severe Pain). The total pain dimension subparametric is the sum of the sensory dimension and the affective dimension of the pain. Total pain intensity is measured with a 6-point Likert-type scale (0-No pain, 5-Unbearable Pain). A high score indicates a high level of pain.

    12 weeks

  • Menstruation Attitude Questionnaire

    Valuated subdimensions include menstruation as a deliberating event, menstruating as a bothersome event, menstruation as a natural event, anticipation and prediction of the onset of menstruation, and denial of any effects of menstruation. The scale is evaluated with a 5-point Likert-type." A high mean score indicates a "positive" attitude toward menstruation.

    12 weeks

  • Menstruation Symptom Questionnaire

    It contains 24 items. It is a 5-point Likert type scale. Participants are asked to evaluate the symptoms that occur during menstruation as a-never (1), b-rarely (2), c-sometimes (3), d-often (4) and e-always (5). The overall score of the scale is calculated by taking the average of the total score obtained from the scale items. A higher score indicates that the symptoms are experienced more clearly.

    12 weeks

  • Visual Analogue Scale (VAS)

    The Visual Analogue Scale (VAS) is used to convert non-numerical values to digital. The value 0 means I have no pain, 10 means I have unbearable pain. The person marks his pain on this ruler. It measures the intensity of the pain.

    12 weeks

Study Arms (2)

Reflexologic Magnetic Insoles Group

ACTIVE COMPARATOR

Participants will place the insoles inside their shoes and use them for at least 7 hours a day, every day, for 12 weeks.

Device: Reflexologic Magnetic Insole Group

Orthopedic Insoles Group

SHAM COMPARATOR

Participants will place the insoles inside their shoes and use them for at least 7 hours a day, every day, for 12 weeks.

Device: Orthopedic Insole Group

Interventions

Reflexologic magnetic insole will be used for at least 7 hours a day, every day, for 12 weeks in participants diagnosed with primary dysmenorrhea. Then the effectiveness of the insoles will be compared.

Reflexologic Magnetic Insoles Group

Orthopedic insole (sham) will be used for at least 7 hours a day, every day, for 12 weeks in participants diagnosed with primary dysmenorrhea. Then the effectiveness of the insoles will be compared.

Orthopedic Insoles Group

Eligibility Criteria

Age18 Years - 30 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsSince dysmenorrhea is a problem seen in the menstrual cycle in women, female participants will be included in the study.
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Having been diagnosed with primary dysmenorrhea
  • Visual Analogue Scale (VAS) value is 3 and above
  • The patient has cooperation
  • Having regular menstruation

You may not qualify if:

  • Getting pregnant during treatment
  • Using analgesic medication
  • Visual Analogue Scale (VAS) value should be between 0-3
  • Having pain in another part of the body

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Istanbul Medipol University

Istanbul, 34815, Turkey (Türkiye)

Location

MeSH Terms

Conditions

DysmenorrheaPain

Condition Hierarchy (Ancestors)

Menstruation DisturbancesPathologic ProcessesPathological Conditions, Signs and SymptomsPelvic PainNeurologic ManifestationsSigns and Symptoms

Study Officials

  • Gizem BOZTAŞ ELVERİŞLİ, Ph.D

    Medipol University

    STUDY DIRECTOR

Central Study Contacts

Gizem BOZTAŞ ELVERİŞLİ, Ph.D

CONTACT

Muhammed Çağrı ELVERİŞLİ, M.D

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: two groups; treatment group and sham group
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

April 6, 2024

First Posted

April 25, 2024

Study Start

May 1, 2024

Primary Completion

August 1, 2024

Study Completion

September 1, 2024

Last Updated

April 25, 2024

Record last verified: 2024-04

Data Sharing

IPD Sharing
Will not share

Locations